{'52WeekChange': 0.3030405,
 'SandP52WeekChange': 0.0644362,
 'address1': '210 East Grand Avenue',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 38.53,
 'askSize': 800,
 'averageDailyVolume10Day': 452750,
 'averageVolume': 1210988,
 'averageVolume10days': 452750,
 'beta': None,
 'beta3Year': None,
 'bid': 38.51,
 'bidSize': 1100,
 'bookValue': 4.842,
 'category': None,
 'circulatingSupply': None,
 'city': 'South San Francisco',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 39.245,
 'dayLow': 38.03,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -20.209,
 'enterpriseToRevenue': None,
 'enterpriseValue': 4394455552,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 42.27657,
 'fiftyTwoWeekHigh': 55,
 'fiftyTwoWeekLow': 17.43,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 62534149,
 'forwardEps': -2.6,
 'forwardPE': -14.834616,
 'fromCurrency': None,
 'fullTimeEmployees': 215,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0.38799998,
 'heldPercentInstitutions': 0.57578,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/allogene.com',
 'longBusinessSummary': 'Allogene Therapeutics, Inc., a clinical stage '
                        'immuno-oncology company, develops and commercializes '
                        'genetically engineered allogeneic T cell therapies '
                        'for the treatment of cancer. The company is '
                        'developing UCART19, an allogeneic chimeric antigen '
                        'receptor (CAR) T cell product candidate, which is in '
                        'Phase I clinical trials for the treatment of '
                        'pediatric and adult patients with R/R CD19 positive '
                        'B-cell ALL; ALLO-501, an anti-CD19 allogeneic CAR T '
                        'cell product candidate that is in Phase I clinical '
                        'trial for the treatment of R/R non-Hodgkin lymphoma; '
                        'and ALLO-501A for the treatment R/R large B-cell '
                        'lymphoma or transformed follicular lymphoma. It is '
                        'also developing ALLO-715, an allogeneic CAR T cell '
                        'product candidate that is in a Phase 1 clinical trial '
                        'for treating R/R multiple myeloma; ALLO-819, an '
                        'allogeneic CAR T cell product candidates for the '
                        'treatment of acute myeloid leukemia; ALLO-647, an '
                        'anti-CD52 monoclonal antibody; CD70 to treat renal '
                        'cell cancer; and DLL3 for the treatment of small cell '
                        'lung cancer and other aggressive neuroendocrine '
                        'tumors. The company has license and collaboration '
                        'agreements with Pfizer Inc.; Servier; Cellectis S.A.; '
                        'and Notch Therapeutics Inc., as well as clinical '
                        'trial collaboration agreement with SpringWorks '
                        'Therapeutics, Inc. Allogene Therapeutics, Inc. was '
                        'founded in 2017 and is headquartered in South San '
                        'Francisco, California.',
 'longName': 'Allogene Therapeutics, Inc.',
 'market': 'us_market',
 'marketCap': 5353091584,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_558022022',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -207488000,
 'nextFiscalYearEnd': 1640908800,
 'open': 39,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '650 457 2700',
 'previousClose': 39.45,
 'priceHint': 2,
 'priceToBook': 7.9657164,
 'priceToSalesTrailing12Months': None,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 39.245,
 'regularMarketDayLow': 38.03,
 'regularMarketOpen': 39,
 'regularMarketPreviousClose': 39.45,
 'regularMarketPrice': 39,
 'regularMarketVolume': 618311,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 138788992,
 'sharesPercentSharesOut': 0.0967,
 'sharesShort': 13420046,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 13253446,
 'shortName': 'Allogene Therapeutics, Inc.',
 'shortPercentOfFloat': 0.1625,
 'shortRatio': 9.92,
 'startDate': None,
 'state': 'CA',
 'strikePrice': None,
 'symbol': 'ALLO',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -1.996,
 'twoHundredDayAverage': 31.609137,
 'volume': 618311,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.allogene.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '94080'}